Advertisement

CNS Drugs

, Volume 32, Issue 6, pp 559–565 | Cite as

Tailoring Treatment in Polymorbid Migraine Patients through Personalized Medicine

  • Leda Marina Pomes
  • Giovanna Gentile
  • Maurizio Simmaco
  • Marina Borro
  • Paolo Martelletti
Commentary

Notes

Compliance with Ethical Standards

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical statement

All the described procedures are conducted in compliance with the latest version of the Declaration of Helsinki and according to clinical guidelines.

References

  1. 1.
    Hagen K, Åsberg AN, Uhlig BL, Tronvik E, Brenner E, Stjern M, Helde G, Gravdahl GB, Sand T. The epidemiology of headache disorders: a face-to-face interview of participants in HUNT4. J Headache Pain. 2018;19:25.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Steiner TJ, Stovner LJ, Vos T, Jensen R, Katsarava Z. Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain. 2018;19:17.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    van Os HJA, Mulder IA, Broersen A, Algra A, van der Schaaf IC, Kappelle LJ, Velthuis BK, Terwindt GM, Schonewille WJ, Visser MC, Ferrari MD, van Walderveen MAA, Wermer MJH, DUST Investigators. Migraine and cerebrovascular atherosclerosis in patients with ischemic stroke. Stroke. 2017;48:1973–5.CrossRefPubMedGoogle Scholar
  4. 4.
    Seidel S, Beisteiner R, Manecke M, Aslan TS, Wöber C. Psychiatric comorbidities and photophobia in patients with migraine. J Headache Pain. 2017;18:18.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Rainero I, Govone F, Gai A, Vacca A, Rubino E. Is migraine primarily a metaboloendocrinedisorder? Curr Pain Headache Rep. 2018;22:36.CrossRefPubMedGoogle Scholar
  6. 6.
    de Tommaso M, Sciruicchio V, Delussi M, Vecchio E, Goffredo M, Simeone M, Barbaro MGF. Symptoms of central sensitization and comorbidity for juvenile fibromyalgia in childhood migraine: an observational study in a tertiary headache center. J Headache Pain. 2017;18:59.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Lionetto L, Borro M, Curto M, Capi M, Negro A, Cipolla F, Gentile G, Martelletti P. Choosing the safest acute therapy during chronic migraine prophylactic treatment: pharmacokinetic and pharmacodynamic considerations. Exp Opin Drug Metab Toxicol. 2016;12:399–406.CrossRefGoogle Scholar
  8. 8.
    Martelletti P. The journey from genetic predisposition to medication overuse headache to its acquisition as sequela of chronic migraine. J Headache Pain. 2018;19:2.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Ferrari A, Baraldi C, Licata M, Rustichelli C. Polypharmacy among headache patients: a cross-sectional study. CNS Drugs. 2018;32:1.  https://doi.org/10.1007/s40263-018-0522-8.CrossRefGoogle Scholar
  10. 10.
    Lionetto L, Gentile G, Bellei E, Capi M, Sabato D, Marsibilio F, Simmaco M, Pini LA, Martelletti P. The omics in migraine. J Headache Pain. 2013;14:55.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Gentile G, Chiossi L, Lionetto L, Martelletti P, Borro M. Pharmacogenetic insights into migraine treatment in children. Pharmacogenomics. 2014;15:1539–50.CrossRefPubMedGoogle Scholar
  12. 12.
    Silberstein SD, Dodick D, Freitag F, Pearlman SH, Hahn SR, Scher AI, Lipton RB. Pharmacological approaches to managing migraine and associated comorbidities—clinical considerations for monotherapy versus polytherapy. Headache. 2007;47:585–99.CrossRefPubMedGoogle Scholar
  13. 13.
    Krymchantowski AV, Bigal ME. Polytherapy in the preventive and acute treatment of migraine: fundamentals for changing the approach. Exp Rev Neurother. 2006;6:283–9.CrossRefGoogle Scholar
  14. 14.
    Palleria C, Di Paolo A, Giofrè C, Caglioti C, Leuzzi G, Siniscalchi A, De Sarro G, Gallelli L. Pharmacokinetic drug–drug interaction and their implication in clinical management. J Res Med Sci. 2013;18:601–10.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. DrugBank 3.0: a comprehensive resource for ‘omics’ research on drugs. Nucleic Acids Res. 2011;39((Database issue)):D1035–41.CrossRefPubMedGoogle Scholar
  16. 16.
    Borro M, Gentile G, Cipolloni L, Foldes-Papp Z, Frati P, Santurro A, Lionetto L, Simmaco M. Personalised healthcare: the DiMA clinical model. Curr Pharm Biotechnol. 2017;18:242–52.CrossRefPubMedGoogle Scholar
  17. 17.
    Borro M, Simmaco M, Aceti A, Barni S, De Luca A, Fineschi V, Frati P, Girardi P, Miozzo M, Nati G, Nicoletti F, Santini D, Marchetti P. H2020 and beyond: skip discrepancy between theory and practice of personalized medicine. A position paper by the Italian Society of Personalized Medicine. Curr Pharm Biotechnol. 2016;17:926–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329:15–9.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Yale SH, Glurich I. Analysis of the inhibitory potential of Ginkgo biloba, Echinacea purpurea, and Serenoa repens on the metabolic activity of cytochrome P450 3A4, 2D6, and 2C9. J Altern Complementary Med. 2005;3:433–9.CrossRefGoogle Scholar
  20. 20.
    Williamson EM. Interactions between herbal and conventional medicines: the role of cytochrome P450 enzymes and p-glycoprotein. Pharmacologyonline. 2006;2:200–5.Google Scholar
  21. 21.
    Gaudineau C, Beckerman R, Welbourn S, Auclair K. Inhibition of human P450 enzymes by multiple constituents of the Ginkgo biloba extract. Biochem Biophys Res Commun. 2004;318:1072–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Yin OQ, Tomlinson B, Waye MM, Chow AH, Chow MS. Pharmacogenetics and herb–drug interactions: experience with Ginkgo biloba and omeprazole. Pharmacogenetics. 2004;14:841–50.CrossRefPubMedGoogle Scholar
  23. 23.
    Deng Y, Bi HC, Zhao LZ, Wang XD, Chen J, Ou ZM, Ding L, Xu LJ, Guan S, Chen X, Zhou SF, Huang M. Induction of cytochrome P450 3A by the Ginkgo biloba extract and bilobalides in human and rat primary hepatocytes. Drug Metab Lett. 2008;2:60–6.CrossRefPubMedGoogle Scholar
  24. 24.
    Hellum BH, Hu Z, Nilsen OG. The induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary human hepatocytes. Basic Clin Pharmacol Toxicol. 2007;100:23–30.CrossRefPubMedGoogle Scholar
  25. 25.
    Wang LS, Zhu B, Abd El-Aty AM, Zhou G, Li Z, Wu J, Chen GL, Liu J, Tang ZR, An W, Li Q, Wang D, Zhou HH. The influence of St. John’s Wort on CYP2C19 activity with respect to genotype. J Clin Pharmacol. 2004;44:577–81.CrossRefPubMedGoogle Scholar
  26. 26.
    Perloff MD, von Moltke LL, Störmer E, Shader RI, Greenblatt DJ. Saint John’s wort: an in vitro analysis of P-glycoprotein induction due to extended exposure. Br J Pharmacol. 2001;134:1601–8.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Residency Program in Laboratory MedicineGabriele d’Annunzio UniversityChietiItaly
  2. 2.Department of Neurosciences, Mental Health and Sensory OrgansSapienza UniversityRomeItaly
  3. 3.Department of Clinical and Molecular MedicineSapienza University of RomeRomeItaly
  4. 4.Internal Medicine and Emergency Medicine UnitSant’Andrea HospitalRomeItaly
  5. 5.Regional Referral Headache CenterSant’Andrea HospitalRomeItaly

Personalised recommendations